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 Abstract 
Accumulation of neutral lipids, in particular triglycerides, in non-adipocytes is 
highly related to the development of insulin resistance and its consequences, type-2 
diabetes and cardiovascular diseases. The accumulation of triglycerides occurs in 
so-called lipid droplets in the cytosol. The lipid droplet is a highly dynamic 
organelle consisting of a core of neutral lipids surrounded by a monolayer of 
amphipathic lipids and proteins. The mechanism of assembly of these droplets is 
poorly understood and the main aim of this thesis was to investigate this 
mechanism at the molecular level. Another aim was to determine the relationship 
between lipid storage and insulin sensitivity of the cell. 
  
In paper I, gain- and loss-of-function experiments showed that phospholipase D1 
promotes the formation of lipid droplets. In addition, a cytosolic protein required 
for assembly of the droplets was isolated and identified as the extracellular 
regulated kinase 2 (ERK2). The importance of ERK2 in the formation of lipid 
droplets was confirmed in intact cells using gain- and loss-of-function experiments. 
Both PLD1 and ERK2 were shown to be necessary for the effect of insulin on lipid 
droplet biosynthesis. Finally, ERK2 was shown to exert its effects through 
phosphorylation of the motor protein dynein. 
  
Lipid droplets are formed as primordial structures with a diameter of 0.1–0.4 µm. 
In paper II, it was found that these primordial droplets grow in size by a fusion 
process that is independent of triglyceride biosynthesis. This conclusion was based 
on investigations in a cell-free system, on pulse-chase experiments in intact cells, 
and by 3D reconstructions of time-lapse studies of fluorescent droplets in intact 
cells. Intact microtubules and dynein were found to be essential for fusion between 
the droplets. The mechanism behind the fusion process was investigated further in 
paper III. The SNARE proteins SNAP23, VAMP4, and syntaxin5 were shown to 
be present on lipid droplets and to mediate their fusion. Previously described co-
factors for SNARE-mediated fusion events (NSF and α-SNAP) were also found to 
be present on droplets.  
 
It is well known that SNAP23 also mediates the insulin-stimulated fusion between 
transport vesicles containing the glucose transporter 4 (GLUT4) and the plasma 
membrane—a process that is essential for insulin-stimulated glucose uptake. 
Treatment of cells with oleic acid caused massive accumulation of lipid droplets, 
and also translocation of SNAP23 from the plasma membrane to sites within the 
cell, including lipid droplets. This was paralleled by an ablation of insulin-
stimulated glucose uptake—an effect that was totally reversed by overexpression of 
SNAP23. Thus, SNAP23 may be a molecular link between insulin resistance and 
neutral lipid storage. 
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 Introduction 
General introduction 
Some diseases have one very simple underlying mechanism that 
directly causes the development and progression of symptoms. 
Examples of such diseases are those in which one single gene is 
affected, causing a specific protein defect that in turn causes 
development of the disease.  
 
Many diseases have more complex causality, however, where 
multiple factors contribute to their development and progression. 
Among these complex diseases, the development of type-2 
diabetes (T2D) might be the ultimate challenge. The complexity 
of T2D has prevented rapid scientific progress, as the condition 
is characterized by an intriguing relationship between the adipose 
tissue, the liver, the pancreas, and skeletal muscle. Even more 
challenging is the long period between the initial disturbance and 
onset of symptoms, with the involvement of both environmental 
and genetic factors. 
 
Advances in new techniques during the past decade, has 
provided us with new insights into the mechanisms underlying 
T2D. The importance of turnover and storage of lipids in this 
condition has been highlighted recently. 
 
In this thesis, my aim has been to elucidate the mechanism of 
cellular lipid storage, and also to study how that process may be 
connected to the development of insulin resistance, which is the 
first sign of development of diabetes.  
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 Insulin Resistance and Type-2 Diabetes 
The world faces a pandemic of type-2 diabetes mellitus (T2D), 
something that has attracted the attention not only of scientists, 
but also of the popular media. In the United States, diabetes is 
already the leading cause of blindness in adults of working age2, 
end-stage renal disease, and non-traumatic loss of limbs3. It is 
also the fifth leading cause of death4. The most accurate data 
regarding prevalence in Europe come from Italy, where the cost 
of T2D was recently estimated to be 5 billion euros, which 
amounts to more than 6% of the total private and public 
healthcare expenditure5. The International Diabetes Federation 
(IDF) anticipates that the worldwide incidence of diabetes among 
those aged 20–79 years will increase by around 70% in the next 
20 years, from 184 million in 2003 to 333 million in 2025. This 
increase will affect all global regions, with projected increases 
ranging from 21% in Europe to 111% in Africa6. 
 
T2D is characterized by an inability to secrete sufficient amounts 
of insulin into the bloodstream. This causes defective glucose 
uptake and results in increased circulating concentrations of 
glucose, which in turn leads to major organ dysfunction and 
death. The development of T2D occurs over more than a decade, 
and is initiated by a defect in the response to insulin — insulin 
resistance. As the cellular insulin signal is reduced, glucose 
cannot be cleared from the blood, which causes the pancreatic 
beta cells to produce more insulin. This overproduction 
compensates for the reduced insulin sensitivity, and can disguise 
the pathological condition for years. Eventually, however, the 
pancreas fails to overcome the ablated insulin response, and 
glucose concentrations rise in the bloodstream. At this point, 
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 T2D has developed and can be diagnosed. Thus, the initial event 
in the development of type-2 diabetes is insulin resistance 
(reviewed in7-9). 
 
There are no clear explanations as to what causes this initial 
disturbance, which drives the development of T2D. Many 
associations have been established between insulin resistance 
and other factors, but no causative relationship has been proven 
in man. One important factor is the increased concentration of 
plasma-free fatty acids derived from adipose tissue triglycerides. 
Such fatty acids adversely affect the insulin signal. Another 
important factor is inflammation of the adipose tissue and the 
release of inflammatory cytokines—factors also known to 
disrupt insulin signaling (reviewed in8,9). In recent years, a new, 
important factor has been identified: lipid accumulation within 
muscle cells (intramyocellular lipids). 
 
A possible relationship between skeletal muscle triglycerides 
(the dominant neutral lipid) and insulin resistance independently 
of obesity was first proposed in the mid-1980s, when increased 
triglyceride content in skeletal muscle was found in 
normoglycemic, hyperinsulinemic dogs with low plasma 
triglycerides10. Further and more direct support for this concept 
was provided in 1991, when a correlation between insulin 
resistance and the amount of triglycerides was observed in 
muscles of mice11. In 1988, the first evidence of a possible role 
of increased skeletal muscle triglycerides in the development of 
insulin resistance in humans was published. Hyperinsulinemic 
subjects with T2D had several-fold increased triglyceride 
concentrations in muscle extracts12.  
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More recently, non-invasive methods such as proton magnetic 
resonance spectroscopy for detection and quantification of 
triglycerides (and other lipids) in man have been developed. This 
allows discrimination between triglycerides within muscle cells 
and neutral lipids in extramyocellular adipose cells13. A number 
of studies have thereafter shown a strong association between 
intramyocellular lipids and insulin resistance, independently of 
obesity, fasting plasma glucose, and age14,15. Thus, accumulation 
of neutral lipids within muscle cells is a major marker of insulin 
resistance. This marker precedes any other measurable analytical 
marker in the early development of insulin resistance leading to 
T2D.  
 
It is, however, unclear whether intramyocellular neutral lipids 
cause the insulin resistance, or whether these are merely a 
marker of disease. It is clear that metabolites derived from 
increased triglyceride turnover in muscle could cause ablation of 
the insulin signal. Diacylglycerol, long-chain fatty acids, and 
ceramides have been especially implicated in affecting the kinase 
cascade following insulin stimulation16. It is also clear that the 
levels of such metabolites are elevated in individuals with insulin 
resistance17, but whether or not there is a causative association 
between intramyocellular accumulations and insulin resistance 
remains controversial. Recently, this question has been addressed 
in animal studies by specific overexpression of triglyceride 
synthesizing enzymes within the liver. The results have been 
contradictory; one study involving overexpression of 
glyceraldehyde-3-phosphate acyl transferase (GPAT) in the liver 
resulted in major accumulation of triglycerides and in insulin 
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 resistance18. Another study, however, showed that 
overexpression of diacylglycerol acyltransferase 1 (DGAT1), 
which is the enzyme that catalyses the final step in triglyceride 
synthesis, did not have any effect on insulin resistance19. To date, 
no studies involving increased quantities of neutral lipids within 
skeletal muscle, with concomitant insulin signaling, have been 
published. Thus, there is no clear evidence at present to show 
whether neutral lipids in muscle cause insulin resistance or 
whether they simply act as a marker of disease.   
Triglyceride biosynthesis 
For a proper understanding of cellular storage of neutral lipids 
and its consequences, an overview of neutral lipid biosynthesis is 
necessary. The most abundant neutral lipids in all cells are 
triglycerides. These are the major constituents of lipid droplets 
(see below), forming the neutral core. This organization allows 
efficient storage of highly hydrophobic molecules, which would 
be difficult to handle in any other way. Also, the formation of 
triglycerides neutralizes free fatty acids—which are extremely 
hazardous to the cell in the free form, as they can act as 
detergents at low concentrations. 
 
Triglyceride biosynthesis begins with glycerol 3-phosphate, 
which is acylated by acyl coenzyme A (acyl CoA)—a reaction 
catalyzed by glycerol phosphate acyltransferase (GPAT). The 
next step is one additional acylation by acyl CoA, catalyzed by 
monoacylglycerol acyltransferase (MPAT). The di-acitylated 
product from these reactions is called phosphatidic acid. 
Phosphatidic acid can either be used for phospolipid biosynthesis 
or hydrolyzed by a phosphatidase to generate diacylglycerol 
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 (DG). This molecule can then be acylated with acyl CoA to 
triacylglycerol, a reaction catalyzed by diacylglycerol acyl 
transferases 1 and 2 (DGAT). 
Storage of cellular neutral lipids: lipid droplets 
Virtually all cells have the ability to store neutral lipids as lipid 
droplets in the cytoplasm. These droplets have a core of neutral 
lipids (cholesterol esters and triglycerides), surrounded by a 
monolayer of phospholipids20. The surface of the droplets is also 
coated with various proteins. To date, using proteomic 
approaches, more than 100 proteins have been reported to 
localize to the surface of the droplet, but only a small proportion 
of these have been verified using other techniques21. The most 
well-known proteins associated with lipid droplets are the PAT 
domain proteins, which include perilipin, adipocyte 
differentiation-related protein (ADFP), tail interacting protein 47 
(TIP47), lipid storage droplet protein 5 (LSDP5, also known as 
MLDP or OXPAT) and S3-1222. These proteins will be discussed 
in detail later. Beyond these, Rab 1823,24, caveolin25, vimentin26, 
and enzymes involved in the synthesis of inflammatory cyotkines 
have been found on the droplet surface27. Enzymes involved in 
the hydrolyzation of triglycerides, together with co-factors, have 
also been reported to be present—at least transiently—on 
droplets28-31.  
 
In vitro studies on purified microsomal membranes have shown 
that lipid droplets can be formed from this compartment in 
response to cytosolic activators, independently of triglyceride 
synthesis. Thus, lipid droplets originate from the endoplasmatic 
reticulum or the Golgi apparatus32. This corresponds well with 
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 the intracellular distribution of the diacylglycerol acyl transferase 
(DGAT) protein33, which catalyzes the last step in triglyceride 
biosynthesis—the formation of triglycerides from diacylglycerol 
and acyl-CoA. Studies using freeze-fracture electron microscopy 
also support the idea of droplets originating from the microsomal 
membrane, as continuous sheets of membrane between droplets 
and the membrane of the endoplasmatic reticulum can be found, 
suggesting a possible site of droplet formation34. There have also 
been studies reporting lipid droplet formation from the plasma 
membrane of isolated adipocytes35.  
 
The exact mechanism of formation of lipid droplets is still not 
fully understood, but the most cited model involves synthesis of 
triglycerides into the microsomal membrane, oiling out between 
the luminal and cytoplasmatic membranes, and then budding of 
the cytoplasmatic leaflet (Figure 1), forming a cytosolic lipid 
droplet20,36.  
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Figure 1. Model of lipid droplet biosynthesis, based on previous 
studies using an in vitro system for lipid droplet biosynthesis 
from microsomal membranes. Diacylglycerol acyltransferase 
(DGAT) catalyses the formation of triglycerides, that resides 
between the leaflets of the microsomal membrane. Thereafter,a 
lipid droplet is formed in response to the activity of  
Phospholipase D (PLD) and a cytosolic activator. 
 
The lipid droplets are formed as small (0.2-µm diameter) 
spherical structures32, and when observed in the cell they usually 
have a very heterogeneous size distribution in the 0.2- to 10-µm 
diameter range. In adipocytes, however, the lipid droplet can 
become more than 25 µm in diameter. The cause of these size 
differences has not been investigated yet; nor has the underlying 
mechanism. The small, newly formed droplets could either grow 
by synthesis of core and surface lipids or expand by fusing with 
each other. 
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 Once formed, the lipid droplets are involved in the turnover of 
triglycerides in the cell37. Lipases can bind reversibly to the 
droplets and catalyse the hydrolysis of triglycerides into 
diglycerides and fatty acids22. This process is dependent on 
hormonal activation and protein-protein interactions between 
lipases and specific proteins on the surface of the lipid droplet22.  
 
Lipid droplets in different types of cell are not identical. For 
example, as mentioned above, there are very large droples in 
adipocytes (around 25 µm in diameter) and there are very small 
droplets in skeletal muscle (less than 1 µm in diameter).  
The PAT-domain protein family 
The biology of lipid droplets is determined by the proteins they 
interact with. Five structural proteins (PAT proteins) have been 
reported to be associated with the droplet surface, and therefore 
deserve special attention. 
 
The PAT-domain protein family is named after the initial letters 
of the first three members identified; perilipin, ADFP (adipocyte 
differentiation-related protein) and TIP47 (tail interacting protein 
47).  Alternatively, the name may originate from the close 
similarity between the N-terminal regions of these proteins: 
perilipin amino-terminal (PAT). The members of the family are 
characterized by 1) a localization to lipid droplets, and 2) a 
similarity to ADFP or perilipin at either the amino terminus or 
the carboxy terminus22. Apart from perilipin, ADFP and TIP47, 
S3-12 and lipid storage droplet protein 5 (LSDP5) have also been 
added to the group. LSDP5 is also known as OXPAT, MLDP, or 
PAT-138,39.  
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Apart from binding to lipid droplets, PAT-domain proteins also 
share several common features regarding structure, genome 
distribution, and regulation (described below). 
 
Perlipin, ADFP, and TIP47 have high sequence identity within 
the amino-terminal PAT-1 domain, but weaker homology in the 
central region and carboxy-terminal PAT-2 domain40,41. The 
amino-terminal segment of S3-12 shares limited identity with the 
PAT-1 domain, but the remainder of the protein shows 
significant homology with ADFP and TIP47 at the carboxy 
terminus. LSDP5 is similar to ADFP and TIP47 (55% and 51% 
identity/homology [choose one] over the entire protein), with 
highest homology at the PAT-1 domain42,43. In mice, the genes 
encoding perilipin and ADFP are located on chromosomes 741 
and 444, respectively, and the genes for TIP47, S3-12, and 
LSDP5 are on chromosome 1738. Genetic analysis suggests that 
the S3-12 and LSDP5 genes might have evolved from gene 
duplication of the TIP47-gene38. 
 
There is also similarity at the exon-intron level, where ADFP, 
TIP47, and LSDP5 have identical exon-intron boundaries38,41,44. 
Perilipin and S3-12 also have similar exon-intron bounderies at 
the amino terminus, but they differ at the carboxy-terminal end 
of the protein38. 
 
Perilipin was the first PAT-domain protein to be identified, and 
impressive functional studies have helped to reveal a specific 
role of the protein in the regulation of lipolysis (see below). 
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 However, the roles of ADFP, TIP47, S3-12, and LSDP5 have not 
been elucidated in such great detail.  
Perilipin 
Perilipin was initially identified as a protein phosphorylated by 
protein kinase A (PKA) in lipolytically stimulated adipocytes45. 
The protein was found to be located in lipid droplets, and to be 
expressed only in adipocytes and steriogenic cells46. Perilipin has 
a single-copy gene that gives rise to three isoforms (A, B, and C) 
as a result of alternative splicing41. Perilipin A is by far the most 
abundant, and shares its N-terminal sequence with perilipin B. 
Perilipin C has not been studied yet in any detail47.   
 
Functional studies on perilipin A in the past two decades have 
elucidated a specific role for perilipin in the turnover of 
adipocyte triglycerides. Perilipin A replaces ADFP as the major 
protein coating lipid droplets in adipocytes during late 
differentiation48. Perilipin A can then be phosphorylated in 
response to lipolytic stimulation (beta-adrenergic ligands). This 
phosphorylation, together with phosphorylation of the hormone-
sensitive lipase (HSL), causes HSL to translocate to the lipid 
droplet and catalyze the hydrolyzation of triglycerides into 
diacylglycerides and fatty acids (reviewed in49). Ectopic 
overexpression of perilipin A in cell lines lacking perilipin 
expression causes a dramatic reduction in lipolytic activity, 
suggesting that unphosphorylated perilipin A may protect lipid 
droplets from lipolysis50.  
 
The vital role of perilipin in adipocyte triglyceride turnover was 
confirmed in perilipin knockout mice, which showed a 
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 substantial increase in basal lipolysis. These mice had a 75% 
reduction in adipose mass, and were resistant to diet-induced 
obesity. Furthermore, the mice did not respond to lipolytic 
stimulation by beta-adrenergic stimulation, and cells derived 
from these mice failed to show translocation of HSL to the lipid 
droplet51,52. 
 
As the role of perilipin in lipolysis became more clear, the gene 
became interesting in human studies on obesity and metabolic 
diseases. The gene for human perilipin is located on chromosome 
15q26, at a locus linked to diabetes, hypertriglyceridemia, and 
obesity. In a study designed to examine the regulation of 
lipolysis in obese and non-obese women, it was found that 
perilipin expression was reduced in obese women (with two- to 
fourfold increased basal and stimulated lipolysis). In fact, there 
was an inverse relationship between adipocyte perilipin and 
plasma glycerol levels. Apart from this, several single-nucleotide 
polymorphisms (SNPs) in the perilipin gene have been strongly 
linked to gender-specific obesity in a variety of population 
studies (reviewed in53).  
 
ADFP 
The second PAT protein to be discovered was ADFP—a fatty 
acid binding protein implicated in adipocyte differentiation, 
which was identified due to its striking homology with perilipin 
at the amino-terminal end 54. The gene was shown to be 
ubiquitously expressed48, and there was also a high correlation 
between levels of expression of the protein and the amount of 
neutral lipid in the cell55.  
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ADFP is located on lipid droplets, and mutational studies have 
ruled out the PAT-1 and PAT-2 domains as being important for 
the binding of ADFP to lipid droplets. Instead, the middle 
domain—including putative alpha-helical regions between amino 
acids 189 and 205—appears to function in directing ADFP to 
droplets56,57.  
 
ADFP is expressed in increasing amounts early in adipocyte 
differentiation, but is then replaced by perilipin at later stages48. 
The phenotype of the ADFP knockout mice does, however, 
suggest that ADFP does not have a vital role in adipocyte 
differentiation (below). ADFP is regulated at the transcriptional 
level by PPARα58-60, but also through post-translational 
degradation by the proteosomal system61,62.  
 
ADFP knockout mice (ADFP -/-) does not have any dramatic 
phenotype. The major effect was seen in the liver, with reduced 
liver triglyceride content63. Furthermore, ADFP -/- mice were 
found to be resistant to diet-induced hepatosteatosis. There were 
no effects on adipocyte differentiation or lipolysis63. Further 
studies on cells from ADFP -/- mice showed that TIP47 was 
directed to the droplets, replacing ADFP64. When TIP47 function 
was ablated using RNAi in ADFP -/- cells, the ability to store 
neutral lipids as lipid droplets was abolished, and exogenously 
added fatty acids were directed to phospholipid biosynthesis64.  
 
Overexpression and RNA interference of ADFP in hepatocyte 
cell lines and primary hepatocytes showed that the formation of 
ADFP-coated cytoplasmatic lipid droplet sequestered 
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 triglycerides from the biosynthesis and assembly of very low 
density lipoproteins (VLDL)65. This was supported by studies 
using antisense RNA directed against expression of liver ADFP, 
which had the effect of reducing liver triglyceride content, 
dyslipidemia, and insulin resistance66.  
 
ADFP is highly expressed in macrophages challenged with 
different lipoprotein species67,68, and in a recent publication 
ADFP was shown to be expressed in macrophage foam cells 
from human atherosclerotic lesions69. The expression of ADFP 
in atherosclerotic plaque also seemed to correlate with the degree 
of symptoms. Recent publications from our group have also 
demonstrated that hypoxia, which can be found in the central 
regions of atherosclerotic plaques, increases the amount of lipid 
droplets together with ADRP protein expression67. 
 
The precise role of ADFP on lipid droplets is not clear, even 
though several reports have provided important clues. There is a 
discrepancy in the literature concerning the importance of ADRP 
in the formation of lipid droplets. Thus, while some authors have 
claimed that elevated levels of ADRP increase the assembly of 
such droplets65, conflicting results have been obtained by 
others49. Moreover, in most cells and animal models, ADFP 
protein expression is increased with treatments that induce lipid 
droplet formation61,62,70. Thus, it is unclear whether ADFP 
increases the amount of lipid droplets or whether lipid droplet 
biosynthesis stabilizes ADFP and thereby increases protein 
expression. But in summary – ADFP is accepted as a marker for 
lipid droplets in non-adipocytes. 
 22
 TIP47 
TIP47 was the third PAT protein to be identified; it was initially 
described as a ubiquitously expressed cytosolic and endosomal 
47-kDa protein involved in the intracellular transport of mannose 
6-phosphate receptors (MPRs) between the trans-Golgi and 
endosomes71,72. TIP47 is believed to act as an effector for the 
Rab9 protein in this process73.  
 
In 2001, however, TIP47 was reported to be present on lipid 
droplets in HeLa cells74. This association was greatly increased 
with fatty acid-stimulated biosynthesis of lipid droplets. TIP47 
appeared to move from the cytosol and onto lipid droplets as a 
response to lipid loading74. This has not been observed for 
ADFP, which is always associated with droplets, and is degraded 
in the absence of neutral lipid. The localization of TIP47 on 
droplets was challenged by other groups75, and even though the 
most recent publications favor the idea of TIP47 being a lipid 
droplet protein, the controversy still remains76-78.  
 
As TIP47 is a relatively soluble protein compared to ADFP and 
perilipin, the carboxy-terminal end has been crystallized and its 
structure determined. Surprisingly, the structure was very similar 
to that of apolipoproteins, with an alpha/beta domain of novel 
topology and four helix bundles resembling the LDL receptor 
binding domain of apolipoprotein E (ApoE)79. The structure 
suggests an analogy between PAT proteins and apolipoproteins, 
with helical repeats interacting with lipid and the ordered C-
terminal region being involved in protein-protein interactions. 
This structural resemblance to ApoE further strengthens the role 
of TIP47 as a lipid droplet protein.  
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To date, there are no known pathways for regulation of TIP47, 
and further studies will be required for us to gain an insight into 
its function in lipid droplets. 
LSDP5/OXPAT/MLDP 
LSDP5 was identified and described by three independent groups 
within a year, and therefore received three different names: lipid 
droplet storage protein 5 (LSDP5), OXPAT, and myocardial 
lipid droplet protein (MLDP)38,39,80. This protein is mainly 
expressed in tissues with high rates of beta oxidation—muscle, 
heart, liver, and brown adipose tissue (BAT)39.   
 
The protein shares high homology with the other PAT-domain 
proteins (especially ADFP, as described above), and is 
transcriptionally regulated by PPARα in striated muscle and 
liver, and by PPARγ in white adipose tissue38,39,80. 
 
The accumulation of triglycerides in response to fatty acid 
treatment of cultured cells is greatly increased with forced 
overexpression of LSDP539. This might possibly be explained by 
a decrease in both basal and stimulated lipolysis38. Thus, the 
protein seems to protect the triglyceride core of lipid droplets 
from degradation in a manner similar to that known for perilipin. 
This has also been suggested by the fact that there was found to 
be a negative correlation between LSDP5 mRNA expression in 
subcutaneous white adipose tissue (WAT) and BMI in 
nondiabetic human subjects. A positive correlation between 
LSDP5 mRNA expression and insulin sensitivity was also 
found39.   
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 S3-12 
Only a small number of reports have investigated S3-12 as a lipid 
droplet protein, even though it was initially described in this 
context81. S3-12 is mainly expressed in white adipose tissue, and 
there is a rather weak sequence homology between this protein 
and the other proteins in the family81.  
 
S3-12 expression is transcriptionally regulated by PPARγ42, and 
appears to function in a manner similar to TIP47—translocating 
to newly formed lipid droplets in response to fatty acid 
stimulation. Apart from this, functional studies are required to 
determine the role of S3-12 in lipid droplets. 
The peroxisome proliferator-activated receptors and 
regulation of PAT-domain proteins 
The tissue expression of the PAT-domain proteins varies (see 
above for details), but their regulation is somewhat similar. 
Several of the PAT-domain proteins are transcriptionally 
regulated by members of the peroxisomal proliferator-activated 
receptors (PPARs). The PPAR family consists of three isoforms: 
PPARα, PPAR ß/δ, and PPARγ which regulate transcription by 
heterodimerization with retinoid X receptors (RXRs) and binding 
to specific PPAR response elements (PPREs) in the promoter 
region of target genes. PPARγ is highly expressed in white 
adipose tissue and macrophages, PPARα is expressed in the 
liver, muscle, and kidney, and PPAR ß/δ is more ubiquitously 
expressed (reviewed in82). LSDP539, S3-1242, and perilipin83 are 
regulated by PPARγ; ADFP59,60 and LSDP580 are regulated by 
PPARα, whereas TIP47 does not appear to be regulated by 
PPARs.  
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Besides transcriptional regulation, the amounts of perilipin 
protein84 and ADFP protein61,62 are regulated post-
transcriptionally by the proteosomal system—a process that is 
dependent on the amount of neutral lipid in the cell. To date, 
post-transcriptional regulation of protein expression has not been 
described for the other PAT proteins. 
Microtubules and motor protein transport 
As most organelles—including lipid droplets—move in a 
coordinated manner within the cell, a description of intracellular 
transport is necessary in order to give the reader a full 
understanding of neutral lipid storage. 
 
One of the major systems for intracellular movement is 
microtubule transport. Microtubules are tube-like structures 
composed of heterodimers of the protein tubulin. They are the 
largest type of cytoskeletal filament with an outer diameter of 
about 25 nm and a wall thickness of 5 nm (reviewed in Brinkley 
-87). 
 
Microtubules are polar structures, a characteristic arising from 
the asymmetry of the tubulin dimer, which is made up of α and β 
subunits85—proteins that are expressed ubiquitously. This 
polarization usually puts the “minus ends” of microtubules at the 
microtubule-organizing center, close to the nucleus, while the 
“plus ends” spread outwards from the organizing center, leading 
to a radial organization. The detail of this radial organization 
differs between cell types. Microtubules are highly dynamic, 
polymerizing and depolymerizing rapidly in response to changes 
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 in ion concentration, GTP levels, and different protein 
interactions (reviewed in Brinkley -87).  
 
Cellular organelles are transported on these intracellular 
microtubule “transport lanes” by the motor proteins dynein and 
kinesin. Transport occurs when the appropriate motor binds to a 
cargo at one end, and simultaneously binds to the microtubule-
rail through the other end. The motor then moves along the “rail” 
by using repeated cycles of coordinated binding and unbinding of 
its two heads, powered by energy derived from hydrolysis of 
ATP.  
 
Motor proteins are able to recognize the microtubule polarity; so 
the organization of the rails combined with the specific motor 
employed determines the direction of transport. Most kinesin-
family motors that have been studied move toward the plus end 
of the microtubules, and thus kinesin-mediated transport is 
usually used to bring cargo toward the cell periphery. In contrast, 
dynein moves in the other direction—toward the minus end of 
the microtubule—and is typically used to move cargo toward the 
center of the cell (and the nucleus) (for review, see86).  
 
Motors also often appear to work together locally; intracellular 
transport often employs multiple motors of different classes on 
the same organelle. For example, multiple dyneins and kinesins 
attach to, and move, single lipid droplets along microtubules in 
bidirectional fashion (back and forth) inside the syncytial 
Drosophila embryo87. 
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 Dynein 
Dyneins are motor proteins that are active on the microtubule 
network. They are found in many different kinds of cells, and 
can be classified into two forms: axonemal and cytoplasmic 
dyneins. Axonemal dyneins are restricted to cileal and flagellar 
movement,while cytoplasmatic dyneins (also called 
“processive”, as they actually generate movement) are active in 
intracellular transport 88.  
 
Only two cytoplasmic dyneins are known: cytoplasmic dynein 
1b, which mainly drives slow transport within the flagellum and 
cytoplasmic dynein 1, which shows an immense range of 
functions during mitosis, in neuronal transport, and in 
maintenance of the Golgi and transport of a wide variety of 
intracellular cargoes such as mRNA, endosomes, viruses, etc. In 
vitro studies have shown that cytoplasmic dynein 1 is a 
processive motor88.  
 
Dynein 1 is a 1.2-MDa protein formed from several subunits. 
Three heavy chains (HCs) of > 500 kDa correspond to the 
number of morphologically identifiable heads, which contain the 
motor domains of the molecule. The dynein HC forms two main 
structures: (1) a 160-kDa N-terminal domain that forms the base 
of the molecule, to which most of the accessory subunits bind, 
and (2) the 380-kDa motor domain. A diversity of accessory 
subunits, referred to as intermediate, light intermediate, and light 
chains are bound to this dynein head. Most, but not all, of these 
subunits are associated with the cargo-binding base of the dynein 
molecule89. 
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 It has been difficult to elucidate the different regulatory 
mechanisms behind dynein motor activity, due to the complexity 
of the protein. It is, however, clear that different protein-protein 
interactions and covalent modifications (e.g. phosphorylation) 
can inhibit or increase dynein activity.  
 
In Drosophila, dynein has been shown to mediate minus-end 
motion of lipid droplets, suggesting that lipid droplets are motile 
on microtubules. No studies on lipid droplet transport in 
mammalian cells have been published87.  
Phospholipase D 
Phospholipase D (PLD) exists in two different isoforms (1 and 2) 
that are ubiquitously expressed; this enzyme catalyzes the 
hydrolysis of phosphatidyl choline into phosphatidic acid and 
choline. Data from different labs have suggested different 
subcellular localizations of PLD1, but the most common 
observation is that it is located at the endoplasmatic reticulum 
(ER)90. The protein has also been reported to translocate between 
the plasma membrane and the ER in response to activation of 
epidermal growth factor stimulation 91. PLD2 has been reported 
to be located only on the plasma membrane92. 
 
PLD2 has a high basal enzymatic activity, while PLD1 requires 
activation through modifications and/or interactions with other 
proteins93.  
 
Molecules known to activate PLD1 include the 
phosphoinositides PI4, 5P2, and PIP3, which all binds to and 
activates PLD1 both in vivo and in vitro94. Besides  these, 
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 different protein kinase C (PKC)  isoforms activate PLD1 both 
dependent and independent on their phosphorylation activity. 
The ADP ribosylation factor 1 and other small GTP-dependent 
proteins such as RhoA, Cdc42Hs, and Rac1 activate PLD1 in a 
GTP-dependent manner in many cell types and tissues 
(activation reviewed in 90).  
Extracellular signal-regulated kinase 
Extracellular signal-regulated kinases 1 and 2 (ERK1 and 2) 
belong to a family of protein kinases named mitogen-activated 
protein kinases (MAPKs). The family also includes c-Jun N-
terminal kinase (JNK(1-3)) and p38 (α, β, γ, and δ). ERK1 and 2 
are 43 and 41 kDa in size, have 83% identity, and are 
ubiquitously expressed. They are part of large signaling 
transduction cascades for a diversity of different cellular 
functions: cell motility, proliferation, differentiation, and 
survival. ERK1 and 2 are located throughout the cell—but as 
much as half of the total amount of protein is situated at the 
microtubules, where it affects polymerization dynamics (reviewd 
in95).  
 
ERK1 and 2 are phosphorylated and thereby activated by MAPK 
kinases (MAP2Ks) named MEK1 and 2, in response to activation 
of different cell receptors: G-protein-coupled receptors, 
cytokines, transforming growth factors, osmotic stress and 
microtubule depolymerization95.  
 
Once activated, ERK1 and 2 exert a variety of effects through 
phosphorylation of different targets. The signal transduction 
secondary to growth factor stimulation is one of the most well-
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 studied pathways of ERK1/2 activation, where ERK1 and 2 are 
translocated to the nuclei and phosphorylate different 
transcription factors that affect expression of target genes95. 
Fusion between transport vesicles and membranes 
One of the central observations in this thesis work has been that 
lipid droplets increase in size by a fusion process. The most well-
characterized fusion process in the cell is the one between 
transport vesicles and target membranes.  
 
Through transport vesicles, in which an aqueous interior is 
surrounded by a membrane, cargo can be shipped from a source 
organelle to specific target membranes96. The vesicles are 
formed from a source membrane using specific protein 
machinery, causing budding into the cytosol. The vesicle is then 
transported to its target membrane and fused with that 
membrane, delivering the cargo to that organelle or to the outside 
of the cell (if the target membrane is the plasma membrane)96. 
 
This fusion process has been studied extensively and 
characterized in detail. The first discovery was that a protein 
named N-ethylmaleimide-sensitive factor (NSF), a cytosolic 
ATPase temporarily bound to membranes, was shown to be vital 
for vesicle-to-membrane fusion97. Thereafter, an important co-
factor for NSF was described—the “soluble NSF adaptor 
protein” (α-SNAP)—which was shown to bind NSF to 
membranes98. Even though these factors were found to be vital 
for the fusion process, their precise function was not clear until a 
family of “SNAP-receptors” (SNAREs) was discovered99. The 
SNAREs act as functional mediators of the fusion event, forcing 
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 membranes together (see below for details). The discovery of 
NSF, α-SNAP, and SNAREs made it possible to outline the 
detailed process in which vesicles fuse to membranes. 
 
First, the vesicle binds loosely to the target membrane through 
weak protein-protein interactions with so-called tethering 
proteins100. This is then followed by more close interactions 
between SNAREs, which are situated both on the vesicle (v-
SNAREs) and on the target membrane (t-SNAREs)101. The 
SNAREs then undergo a conformational change (cis to trans), 
which exert a force on the two membranes—moving them close, 
and forcing them to fuse102. This trans-SNARE complex is 
characterized by four alpha helix bundles twined together (the 
so-called “four-helix bundle)103 with a central affinity point 
called “the zero-plane”. The four alpha helices belong to three 
different SNARE proteins, and their different contributions of 
amino-acid residues to the zero-plane constitutes a basis for 
grouping of the SNAREs: some SNAREs contribute with an 
glutamine (Q-SNAREs), and others contribute with an arginine 
(R-SNAREs)103,104. In order to form a functional SNARE 
complex that is able to fuse membranes, the three SNAREs must 
consist of one Qa-SNARE (contributing with one glutamine at 
the a-position in the zero-plane), one Qbc-SNARE (contributing 
with two glutamines at the b-and c-positions in the zero-plane), 
and one R-SNARE (contributing with one arginine in the zero-
plane)104,105. 
 
Finally, to be ready for the subsequent rounds of transport, the 
SNARE complex must be disassembled. This process is 
catalyzed by the combined action of α-SNAP and NSF. 
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 Interaction of NSF and three α-SNAPs with the SNARE complex 
through ATP hydrolysis leads to the disassembly, through a 
transient 20-S complex. The freed v-SNAREs can then be 
recycled to the donor compartment by retrograde transport, while 
the t-SNARE subunits can be reorganized into functional t-
SNAREs for the next round of fusion events106-108. 
SNAREs  
There are a large number of SNAREs in mammalian cells, and 
they are grouped based on whether they are found on vesicles (v-
SNAREs) or target membranes (t-SNAREs). An alternative 
scheme uses the terminology R- or Q-SNAREs, reflecting the 
presence of an arginine or a glutamine, respectively, at a 
characteristic position within the SNARE motif 109. SNAREs 
also differ in the way they bind to membranes; some bind 
through an integral, transmembrane region while others are 
synthesized on free ribosomes, followed by insertion of the C-
terminal region into the membrane by chaperones110. One small 
group of SNAREs is soluble and binds to membranes using a 
palmoityl anchor, covalently attached to central cysteine 
residues. The VAMPs are examples of tail-inserted SNAREs, 
and SNAP23 of palmoitylated109.  
The insulin-regulated glucose transporter 
GLUT4 is a membrane protein containing 12 transmembrane 
domains. One of the ways in which insulin can influence the 
uptake of glucose in a muscle or fat cell is by increasing the 
amount of the glucose transporter GLUT4 in the plasma 
membrane. Of importance for this increase is the translocation of 
GLUT4 from a cellular storage from to the plasma membrane, a 
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 process that involves a SNARE-mediated fusion 
process(reviewed in111). 
 
Although the GLUT4 activity can be regulated at the 
transcriptional level in some cases (obesity112 and exercise113), 
the major control of GLUT4-mediated glucose uptake is through 
translocation of intracellular GLUT4 to the plasma membrane. 
Under basal conditions, most of the cellular GLUT 4 resides in 
low-density fractions of intracellular membranes. In response to 
stimuli, however, vesicles containing GLUT4 are transported 
from this compartment toward the plasma membrane114. These 
vesicles become tethered to the membrane, and fuse using a 
SNARE complex-containing VAMP4, syntaxin 2 and 
SNAP23115. The stimulus that causes GLUT4 to move to the cell 
surface also inhibits the recycling pathway, where GLUT4 
vesicles are internalized using an endocytotic mechanism. The 
increased translocation to the plasma membrane together with 
reduced internalization causes a net increase in GLUT 4 on the 
cell surface, thus facilitating glucose uptake111. 
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 Aim 
The aim of this thesis has been to describe the biosynthesis of 
lipid droplets, and to identify a molecular link between lipid 
droplets and insulin resistance. Specifically, the following issues 
have been addressed: 
 
1. Identification of insulin-dependent mediators of lipid 
droplet formation. 
2. Clarification of the mechanism by which lipid 
droplets grow in size. 
3. The molecular background behind such growth. 
4. The molecular link between lipid droplet biosynthesis 
and insulin sensitivity. 
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 Summary of results  
Paper I 
PLD1 but not PLD2, is active in lipid droplet biosynthesis 
In previous studies, lipid droplets were shown to be synthesised 
from purified microsomes in an in vitro system. Phospholipase D 
activity and a partially purified cytosolic activator were needed 
to form small lipid droplets32. In this paper, the cytosolic 
activator was identified and its role was studied in living cells. 
The role of PLD was also investigated in living cells – especially 
regarding what isoform was active in lipid droplet biogenesis. As 
insulin induces lipid droplet formation, the question of whether 
PLD and/or the cytosolic activator have any role in the cellular 
response to insulin stimuli was then investigated. 
 
In order to study the intracellular localization of PLD1 and 2, 
immunocyotchemistry was used, which showed that PLD1 was 
located in intracellular compartments while PLD2 was located at 
the plasma membrane. Overexpression of ectopic PLD1 in NIH 
3T3 cells caused a 5.1 ± 2.6-fold increase (mean ± s.d.; n = 7; P 
< 0.001, Mann-Whitney rank sum test) in the total area of oil red 
o-stained lipid droplets, while overexpression of PLD2 had no 
effect on the pool of lipid droplets. Overexpression of PLD1 also 
resulted in increased amounts of triglycerides and ADFP, effects 
that were not seen with PLD2 overexpression. These results 
indicate that PLD1, but not PLD2, regulates the intracellular 
formation of lipid droplets. 
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 The importance of PLD1 was confirmed by the use if loss–of-
function experiments. The siRNA knockdown of PLD1 reduced 
both the amount of oil red o-stained lipid droplets in the cell 
compared to control siRNA (P < 0.001, Mann-Whitney rank sum 
test; 6 independent experiments) and the accumulation of 
triglycerides and ADFP. Taken together, these results indicate 
that PLD1 has an important, rate-limiting role in lipid droplet 
assembly in intact cells. 
 
Identification of a cytosolic activator 
A cytosolic component had been previously reported to activate 
lipid droplet formation in vitro32. This activator was partially 
purified using a chromatographic procedure32. For each 
chromatography step, all fractions were analyzed for ability to 
activate the in vitro system for lipid droplet formation. Most of 
the activity was recovered between 62 and 0 mM (NH4)2SO4 in 
the final hydrophobic interaction chromatography. This fraction 
was analyzed by SDS polyacrylamide gel electrophoresis where 
all bands were cut out, trypsinized and identified by matrix-
assisted laser desorption/ionization time-of-flight (MALDI-
TOF). Three of the proteins identified (ERK2, citrate lyase, and 
adiponectin) were added to the in vitro system as recombinant 
proteins. Citrate lyase and adiponectin did not promote lipid 
droplet formation, whereas ERK2 showed a dramatic effect: 12 ± 
2-fold higher activity than the control fraction. This result 
suggested that ERK2 might be the unidentified cytosolic factor 
working in conjunction with PLD1 to promote lipid droplet 
formation. 
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 ERK2 is active on droplet formation in intact cells 
Transfection of NIH 3T3 cells with the ERK2 gene increased the 
formation of cytosolic lipid droplets 3.0 ± 1.9-fold (mean ± s.d; n 
= 5; P = 0.008, Mann-Whitney rank sum test) when compared to 
a vector encoding GFP as control. As seen for PLD1, ERK2 also 
increased the amount of triglycerides and ADFP protein 
expression.  
 
The role of ERK2 was also examined in loss-of-function 
experiments using siRNA followed by quantification of lipid 
droplets. Compared to control siRNA, ERK2 siRNA 
significantly reduced the formation of Oil Red O-stained lipid 
droplets by 56 ± 14% (mean ± s.d.; n = 6; P = 0.002, Mann-
Whitney rank sum test). Also, levels of ADFP and triglycerides 
were reduced. 
 
Microinjection of active ERK2 protein into NIH 3T3 cells 
resulted in an increase in the amount of lipid droplets in 
comparison to injection of control GFP protein  (P<0.001).  
 
Treatment of NIH 3T3 cells with Ste-Mek113116, which inhibits 
the activation of ERK2, reduced the amount of lipid droplets by 
59 ± 14% (n = 5). Together, these results indicate that ERK2 is 
vital for lipid droplet formation in living cells. 
The ERK2 siRNAs were isoform-specific, indicating that ERK1 
does not promote lipid droplet formation in the absence of ERK2. 
To further examine whether ERK1 might act in this process, 
ERK1 was overexpressed - which resulted in a severalfold 
increase in the level of expression of ERK1 without having any 
 38
 effect on lipid droplet formation. SiRNAs against ERK1 
significantly reduced the amount of ERK1 but had no effect on 
the amount of lipid droplets in the cell. 
Finally, the effects of JNK1, JNK2, p38, and p38ß on lipid 
droplet formation were investigated using siRNA and/or 
inhibitors. SiRNA to p38 or p38ß failed to affect the formation of 
lipid droplets, as was the case for an inhibitor of p38. SiRNAs to 
JNK1 and JNK2 also had no effect, as was the case for JNK 
inhibitor. 
Taken together, these results suggest that the role of ERK2 in 
promoting lipid droplet formation is specific to this MAP kinase 
family member 
Insulin promotes lipid droplet formation through PLD1 and 
ERK2 
Insulin induced lipid droplet formation in serum-starved cells in a 
dose-dependent manner. Knockdown of PLD1 using siRNA 
inhibited the insulin-induced lipid droplet formation by 138 ± 
43% (mean ± s.d.; n = 3; P = 0.005). The ERK2 inhibitor Ste-
Mek113 also reduced the insulin-induced increase in the 
formation of lipid droplets by 73 ± 40% (n = 5, P = 0.004). 
SiRNA to ERK2 gave a similar result, suggesting that inhibition 
of ERK2 inhibits the insulin-stimulated rate of lipid droplet 
formation. Together, these results indicate that PLD1 and ERK2 
are essential for insulin-stimulated lipid droplet biosynthesis. 
 
ERK2 phosphorylates the motor protein dynein, which directs it 
to droplets 
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 Next, the question of whether ERK2 could phosphorylate lipid 
droplet proteins was investigated. ADFP, caveolin, vimentin, 
PLD1, and dynein were analyzed for ERK2 phosphorylation 
using recombinant ERK2 in NIH 3T3 homogenates, followed by 
the PhosphoProtein purification kit and immunoblotting of 
retained fractions. ERK2 phosphorylated dynein only. 
Furthermore, it was shown that dynein is directed to lipid 
droplets through ERK2 phosphorylation. Thus, ERK2 possibly 
exerts its action by phosphorylation of the motor protein dynein. 
In order to assess whether dynein might promote the assembly of 
lipid droplets, 3T3 NIH cells were microinjected either with an 
antibody directed against dynein or a control immunoglobulin. 
The results showed that the antibody to dynein caused a 
significant decrease in the amount of lipid droplets in the cell - by 
63 ± 16% (mean ± s.d.; P = 0.002, t-test). 
Finally, the role of dynein in the fusion between lipid droplets 
was investigated. Cells were injected either with antibodies to 
dynein or with the control immunoglobulin. The droplets were 
then stained with BODIPY and followed using confocal 
microscopy in time-lapse studies, as described in paper II. The 
cells injected with anti-dynein antibodies significantly reduced 
the frequency of fusions (P < 0.001; n = 16 for anti-dynein, n = 
13 for control immunoglobulin). Together, these results indicate 
that dynein is an important player in lipid droplet formation, and 
a potential mediator of the effect of ERK2 effect on the assembly 
of lipid droplets. 
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 Paper II 
Lipid droplets are synthesized as small structures, 200 nm in 
diameter32. When observed in the cell, however, they are much 
larger and heterogenous in size. Thus, in this paper, the 
mechanism of the enlargement of lipid droplets was investigated. 
 
The possibility that lipid droplets grow in size after being formed 
was tested by pulsing NIH 3T3 cells with oleic acid for 2 hours 
followed by a chase for 2 hours in the presence of 20 µmol/L 
triacsin C, a potent inhibitor of triglyceride biosynthesis. After 
the pulse, most lipid droplets were small (< 3 µm). After the 
chase in the presence of triacsin C, however, there were fewer 
small droplets - with a compensatory increase in larger particles. 
The total area of oil red o–stained lipid droplets per cell did not 
change during the chase. These results indicate that small 
droplets can increase in size independently of triglyceride 
biosynthesis. 
 
A likely explanation is that the increase occurs via a fusion 
between droplets. This was tested in confocal analysis of live 
cells by labeling droplets with Nile red dye, or overexpressed 
fluorescent ADFP. Both approaches showed clear fusion events 
(see example in figure 2). Close-up zooms after 3D 
reconstructions ruled out the possibility that the droplets moved 
on top of each other.  
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Figure 2. Fusion between two lipid droplets after 3D 
reconstruction. Complete z-stacks were obtained at 30 seccons 
interval (1-4) followed by 3D-reconstruction. The top two 
droplets are seen fusion with each other. 
An in vitro system was also established to study the process of 
fusion of lipid droplet. NIH 3T3 cells were either transfected 
with ADFP-GFP or incubated with [3H]-palmitic acid to label 
triglycerides. Homogenates from both dishes were then mixed 
and incubated together, followed by immunoprecipitation with 
antibodies to GFP, and isolation of triglycerides. Thirty per cent 
of the [3H]-labeled triglycerides were recovered using such 
precipitations, compared to 6% in control precipitations. This 
indicates that droplets from ADFP-GFP-labeled cells had fused 
with droplets from [3H]-labeled cells.  
Calcium, a known activator of vesicle fusion, increased the 
recovery of labeled triglycerides after ADFP-GFP precipitation 
(63% of the radioactivity could be precipitated with the anti-GFP 
antibody). Thus, the fusion process appeared to be calcium-
dependent. 
Nocodazole, which disrupts the microtubule network in vivo 
reduced the rate of fusions between droplets - as judged from 
pulse chase experiments with Triacsin C and also the in vitro 
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 system for droplet fusion. Thus, a functional microtubule 
network is vital for fusion of lipid droplets. 
Dynein was shown to be vital for droplet formation in the time-
lapse system in paper I, and this was investigated further by the 
use of vanadate—an inhibitor of the ATPase activity of dynein. 
Vanadate also ablated lipid droplet fusions, both in vivo and in 
vitro. Thus, the microtubule network and the motor protein 
dynein are vital factors for the fusion between lipid droplets. 
Paper III 
The aim of this paper was to clarify the molecular mechanism 
behind lipid droplet fusion, and the connection between lipid 
droplet fusions and insulin signaling. 
 
The SNARE machinery is present on lipid droplets 
The SNARE proteins SNAP23, syntaxin5 and VAMP4 were 
observed on isolated lipid droplets together with NSF and α-
SNAP. This was shown by immunoblot of purified lipid droplets, 
co-precipitations against ADFP, and immuno-electron 
microscopy. 
 
SNAP23, VAMP4, and syntaxin-5 are present in a functional 
complex on lipid droplets 
Using immunoprecipitation of cell lysate, VAMP4 and SNAP23 
co-precipitated with syntaxin-5, demonstrating that the three 
SNARE proteins form stable complexes with each other. No 
reactions were seen when control immunoglobulins were used 
for precipitation (data not shown). SNARE complexes are 
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 stabilized with α-SNAP when the ATPase activity of NSF is 
inhibited. Isolated droplets were therefore solubilized and 
incubated with His-tagged recombinant α-SNAP in the presence 
of ATP-γ-S and EDTA. The complexes were then purified using 
immunoaffinity chromatography against the His-tag. The 
retained fractions were immunoblotted against several SNAREs. 
Only SNAP23, syntaxin-5, and VAMP4 were detected with this 
method, indicating that these three SNARE proteins form four-
helix bundles that interact with α-SNAP on lipid droplets. 
Furthermore, it was observed that syntaxin-5 and SNAP23 co-
precipitated with VAMP4 from solubilized lipid droplets, 
supporting a stable interaction between the three SNARE 
proteins. No reaction was seen when control immunoglobulins 
were used for precipitation.
 
Thus, the SNARE proteins identified on lipid droplets are in a 
functional complex. 
 
SNAP23, VAMP4, and syntaxin-5 mediate fusion between lipid 
droplets 
To study whether the SNARE proteins were active on lipid 
droplet fusion, siRNA knockdown of each protein was 
performed, followed by time-lapse analysis of the rate of lipid 
droplet fusion. Such ablation of lipid droplet SNAREs greatly 
reduced the rate of fusions. (A truncated, dominant negative 
SNAP23 was overexpressed, which also caused reduced lipid 
droplet fusion). In addition, microinjection of a dominant-
negative mutant of α-SNAP reduced the rate of lipid droplet 
fusion. As a control, siRNA against syntaxin-2 was also used, 
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 which did not affect lipid droplet fusion. Thus, the SNARE 
proteins found on lipid droplets are vital for the fusion activity. 
 
We also investigated whether the SNAREs found on the droplets 
affected their sizes. SiRNA-mediated depletion of SNAP23, 
syntaxin-5, or VAMP4 resulted in smaller lipid droplets—as 
assessed in three dimensions after confocal microscopy. No 
effect on triglyceride content or biosynthesis was observed, 
though. Microinjection of a dominant-negative mutant of α-
SNAP into cells reduced the size of the lipid droplets, but did not 
influence the total pool of lipid droplets. In summary, these 
results indicate that SNAP23, syntaxin-5, VAMP4, and α-SNAP 
are not only present on the droplets but are also active in the 
fusion between these droplets. 
 
Fatty acid treatment of HL-1 cardiomyocytes divert SNAP23 
from the plasma membrane to intracellular compartments, 
including lipid droplets 
SNAP23 is important both for the fusion between GLUT4-
carrying vesicles and the plasma membrane, and for the fusion 
step in the assembly of lipid droplets. The question of whether 
SNAP23 participates in fatty-acid-induced insulin resistance was 
therefore investigated.  
 
As expected, oleic acid treatment of the cells caused a large 
increase in the pool of lipid droplets. This was paralleled by 
reduced insulin-dependent glucose uptake and translocation of 
GLUT4 to the plasma membrane. Furthermore, the plasma 
membrane pool of SNAP23 was reduced upon oleic acid 
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 treatment, as assessed by both immunocytochemistry and 
subcellular fractionation. There was, however, no effect on the 
total pool of SNAP23. SNAP23 was also increased on lipid 
droplets with fatty acid treatment. Thus, it seems that oleic acid-
treatment results in dissociation of SNAP23 from the plasma 
membrane—to structures in the interior of the cell, including 
lipid droplets. The majority of SNAP23 molecules appear to be 
translocated to the cytosol or to the intracellular membranes, and 
the amount that appears on lipid droplets seems to be dependent 
on the oleic acid-induced increase in the pool size of these 
droplets. 
 
Fatty acid treatment of muscle cells causes insulin resistance, 
which is reversed by overexpression of SNAP23 
As shown by other authors, ablation of SNAP23 function by 
siRNA results in a deficiency in insulin-stimulated glucose 
uptake . This implies that reduction in SNAP23 at the plasma 
membrane during fatty acid treatment might possibly cause 
insulin resistance. In order to test this conclusively, SNAP23 was 
transiently overexpressed during oleic acid treatment while 
observing insulin-dependent glucose uptake and plasma 
membrane translocation of GLUT4. The results showed that the 
fatty acid-induced insulin resistance could be completely restored 
by ectopic SNAP23 expression.  
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In conclusion, it was shown that SNAP23 has a key role in the 
fatty acid-mediated regulation of the insulin sensitivity of the 
cell.
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 Discussion 
The effect of PLD1 on lipid droplets 
In paper I, PLD1 was shown to be important for the formation of 
lipid droplets. This conclusion was based on siRNA knockdown 
in NIH 3T3 fibroblasts, which reduced the amount of lipid 
droplets, and also on overexpression of the enzyme, which 
increased the amount of lipid droplets compared to an inactive 
mutant. The exact mechanism by which PLD1 increases the pool 
of lipid droplets has not been fully elucidated, however. One 
possibility is that PLD1 acts by facilitating the fusion between 
lipid droplets. This is supported by the fact that PLD1 has been 
identified on lipid droplets in NIH 3T3 cells118, and that 
phosphatidic acid has been reported to mediate fusion events 
between transport vesicles and target membranes119. As newly 
formed lipid droplets are undetectable under light microscopy, 
due to their size (2000 Å)32, it may be that PLD1 promotes the 
fusion between such small structures into larger ones (see 
discussion below) - visible by light microscopy. Arguing against 
PLD1 acting only on lipid droplet fusion is the finding that 
siRNA knockdown of PLD1 reduced the amount of cellular 
triglycerides, while overexpression of the enzyme increased the 
amount of triglycerides. This effect cannot be explained solely 
by lipid droplet fusion. 
 
Another possibility is that PLD1 acts by promoting the influx of 
glucose into the cell, which is supported by the fact that PLD1 
has been proven to be active on the plasma membrane in the 
fusion of GLUT4 transport vesicles120, thus increasing glucose 
uptake. Increased glucose uptake may promote triglyceride 
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 synthesis. However, data from an in vitro system suggesting that 
PLD1 acts directly on the microsomal membrane for lipid droplet 
formation32 conflicts with such a hypothesis. Also, PLD1 was 
shown to be mainly located in intracellular compartments such as 
the endoplasmatic reticulum (paper I, supplemental information), 
which argues against a specific role of this protein at the plasma 
membrane in this system. 
 
A third possibility is that PLD1 enzyme activity is vital for the 
formation of lipid droplets from the microsomal membrane to the 
cytosol. This suggestion is supported by the intracellular 
localization of PLD1 at the site where lipid droplets form (the 
endoplasmatic reticulum and the Golgi apparatus; Supplemental 
information – paper I). Some further support for this idea is that 
PLD1 and the product of its enzyme activity, phosphatidic acid, 
are vital for the formation of lipid droplets in an in vitro 
system32. The effect of PA may be related to its ability to 
influence the structure of membranes and facilitate budding 
reactions119, or it may recruit or activate other proteins involved 
in the process121.  
 
In summary, PLD1 has a central role in the formation of 
cytosolic lipid droplets, most likely by a specific effect on lipid 
droplet formation at the endoplasmic reticulum. An additional 
role in promoting fusion between lipid droplets cannot be 
excluded, however. 
 48
 PLD1, but not PLD2, is the active isoform in lipid 
droplet biogenisis 
Using specific overexpression, and dominant negative constructs 
of both PLD1 and PLD2, PLD1 was identified as the isoform 
active in lipid droplet biosynthesis.  
 
This finding is in agreement with published data regarding the 
localization of PLD1 at the endoplasmatic reticulum and the 
Golgi apparatus90.  
 
PLD2 has been reported to be located on the plasma membrane 
exclusively92. Such a location does not fit in with ER synthesis of 
lipid droplets. Some investigators have reported that lipid droplet 
formation is also carried out in the plasma membrane35. 
However, the results presented in paper I are not compatible with 
a role of PLD2 in the assembly of lipid droplets.  
 
Thus, PLD1 is linked to the assembly of lipid droplets and it is 
located at the site of droplet formation. Based on this, one can 
conclude that PLD1 is the most likely isoform to be active in 
lipid droplet biosynthesis. 
ERK2 but not ERK1 is the active isoform for lipid 
droplet biosynthesis 
The previously identified cytosolic protein required for lipid 
droplet assembly32 was isolated and identified as ERK2. Using 
specific siRNAs against ERK1 and ERK2, combined with 
enzyme inhibitors, overexpression and microinjection of purified 
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 enzyme, ERK2 was shown to be the active isoform in lipid 
droplet biosynthesis. We were also able to demonstrate that 
ERK2 phosphorylates the motor protein dynein, thereby 
translocating it to droplets. This was shown in vitro by 
incubating cell homogenates with active ERK2, followed by 
isolation of lipid droplets and phosphoprotein purification. 
As to the finding that ERK2 (and not ERK1) is the active 
isoform in lipid droplet formation, one possibility might be that 
the siRNAs used were not specific for ERK2. Thus, the 
specificities of the respective isoforms were tested by 
immunoblotting against both ERK1 and ERK2 after siRNA 
knockdown. The data presented in paper I show that siRNA 
against ERK2 does not affect ERK1, or control proteins. Thus, 
the effect seen with siRNA against ERK2 could not be explained 
by ablation of ERK1 protein expression. Also, specific siRNA-
mediated knockdown of ERK1 (without affecting ERK2 protein 
levels) failed to affect the amount of lipid droplets. Thus, ERK2 
is most likely to be the isoform specific for lipid droplet 
formation. 
ERK2 could act either by promoting budding of small lipid 
droplets from the microsomal membrane, or by increasing the 
amount of fusion events, providing more droplets that would be 
visible by light microscopy. Such a hypothesis is supported by 
the fact that ERK2 was shown to phosphorylate the motor 
protein dynein, directing it to droplets. Dynein was also shown to 
be vital for the fusion between lipid droplets (papers I and II). 
However, it is possible that ERK2 might influence other 
mechanisms involved in the assembly process. Indeed, the 
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 observation that overexpression of ERK2 increased the 
triglyceride levels while siRNA against ERK2 decreased them, 
argue against a role for ERK2 only in fusion between lipid 
droplets. Unless there is a difference in triglyceride turnover 
between small and large droplets, such an effect cannot be 
explained by an effect only on lipid droplet enlargement. 
This would indicate that ERK2 acts directly on the formation of 
the droplet from the microsomal membrane. This possibility is 
supported by the fact that purified ERK2 alone can activate the in 
vitro system for lipid droplet formation (paper I).  
Thus, based on the results and discussion above, ERK2 most 
likely promotes fusion between lipid droplets by phosphorylation 
of dynein. The possibility that ERK2 might also act earlier in the 
process of lipid droplet biosynthesis cannot be excluded, 
however. Other methods will be required to address this 
question. 
ERK2 and PLD1 as effectors of Insulin stimulated 
lipid droplet biogenesis 
In paper I, data are presented which suggest that insulin acts 
through ERK2 and PLD1 on lipid droplet biosynthesis. This was 
based on the observation that siRNA knockdown of PLD1—or 
inhibitors of ERK2—were able to reduce the effect of insulin on 
lipid droplet formation.  
One possibility is that ERK2 and PLD1 really are activated by 
the signaling cascade downstream of the insulin receptor. As 
discussed previously, ERK2 and PLD1 could then act either on 
 51
 GLUT4 translocation, lipid droplet budding, or lipid droplet 
fusion. This is supported by the fact that both ERK kinases and 
PLD1 have already been reported to be activated by insulin 
signaling kinases120,122. 
The data presented in paper I do not provide evidence for direct 
activation of PLD1 or ERK2, only ablation of the effect of 
insulin on droplets when the enzymes are inhibited. It cannot, 
therefore, be excluded that PLD1 and/or ERK2 act in parallel 
with the insulin signal—being vital for lipid droplet biogenesis 
without direct activation of the insulin signaling cascade. In 
support of this is the fact that lipid droplet formation increases 
when ERK2 or PLD1 are overexpressed without additional 
activation by insulin. 
The movement of lipid droplet on microtubules 
In paper II, we demonstrated a rapid plus-end motion of small 
droplets using time-lapse microscopy with 3D reconstructions. 
This is in agreement with reports from Drosophila87, where 
motor protein-mediated microtubule transport has been 
demonstrated. 
 
Interestingly, we could show that the transport on microtubules 
and the motor protein dynein (see above) were vital for the 
fusion between lipid droplets. Thus, the observed fusion activity 
between droplets was ablated when the microtubule network was 
disrupted using nocodazole, or when dynein was inhibited with 
microinjected antibodies.  
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 Lipid droplet fusion 
In paper II, it was demonstrated that lipid droplets become 
enlarged by fusing with each other. This was demonstrated by 
three different techniques: confocal microscopy of live cells 
followed by 3D reconstruction, analysis of lipid droplet sizes 
with inhibition of triglyceride biosynthesis, and in vitro fusion 
between purified lipid droplets. 
 
It is well known that lipid droplets increase in size secondary to 
fatty acid treatment, for example. One explanation is that the 
droplets contain the complete machinery for synthesis of both 
core and surface material, and enlarge individually; another 
explanation is that they grow by fusion. 
 
Arguing against the possibility that droplets enlarge by 
themselves are data from paper II, which show that lipid droplets 
enlarge independently of triglyceride biosynthesis. Also, no 
complete machinery for lipid biosynthesis has been identified on 
droplets in any of the proteomic studies performed on purified 
droplets31,76,123-125. It would also be difficult to fit the membrane-
spanning triglyceride biosynthesis enzymes with large 
hydrophilic regions at both sides of the membranes, onto a lipid 
droplet with a hydrophobic core surrounded by a monolayer. 
Together, these circumstances would argue against lipid droplet 
enlargement by lipid biosynthesis on the droplet surface. 
 
Instead, the most plausible mechanism for droplet enlargement is 
fusion—i.e. small droplets becoming larger by fusion. This is 
supported by the data presented in paper II.  Using time-lapse, 
individual lipid droplets could be followed in living cells, and the 
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 fusion between droplets could be observed in detail. These 
results—especially the movies provided—clearly demonstrate 
fusions between lipid droplets. 
  
In summary, the data available strongly indicate that droplets do 
indeed grow in size by a fusion process, and not by individual 
enlargement. 
SNARE proteins are present in a complex on lipid 
droplets 
In paper III, data are presented that demonstrate that the SNARE 
proteins SNAP23, syntaxin-5, and VAMP4 are present on lipid 
droplets. Co-factors for the SNARE fusion machinery—α-SNAP 
and NSF—were also found on droplets. Beyond just being 
present on droplets, the SNAREs were found to be in a 
functional complex on the droplets. 
 
As syntaxin-5 and VAMP4 are integral membrane proteins, their 
attachment to the lipid droplet surface would be problematic if 
they were inserted during translation. Syntaxin-5 and VAMP4 
are so-called tail-anchor proteins. They are formed as cytosolic 
proteins and their C-terminal hydrophobic domains are anchored 
to membranes by interaction with chaperone-like proteins as well 
as membrane proteins . Such a mechanism may also anchor 
SNAREs in the amphipathic monolayer that surrounds lipid 
droplets. The C-terminal domain of syntaxin-5 is highly 
hydrophobic, suggesting that it could fit into a monolayer with a 
hydrophobic phase below. I
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n contrast to syntaxin-5, VAMP4 
contains two charged amino acids at its luminally-oriented 
carboxy terminus, which would be difficult to incorporate into 
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 the core of a lipid droplet. However, it is unclear whether lipid 
droplets contain a perfect hydrophobic core. Freeze-fracture 
experiments indicate the presence of internal membrane systems. 
Even a small area containing a lipid-bilayer structure at the 
surface of lipid droplets would be sufficient for VAMP4 
anchoring, and might even provide a target for localization of 
VAMP4. Alternatively, the transmembrane region of VAMP4 
might dip into the lipid-droplet monolayer, leaving the 
hydrophilic tail exposed to the cytosol. 
 
Isolation of lipid droplets with their large amphipathic surface 
covering the extremely hydrophobic core poses problems. Thus, 
such isolations always result in the presence of some 
contaminants. This could possibly pose a problem regarding 
interpretation of the finding of SNAREs on purified droplets. 
This question was assessed by analyzing the presence of other 
(highly expressed) SNAREs, and control proteins. None of the 
other SNAREs (or the control proteins) were present on droplets. 
 
The SNARE proteins identified on droplets in paper III were not 
found in the published articles of proteomic analysis of purified 
lipid droplets31,76,123-125. This could be explained by the immuno-
electron microscopy findings, which demonstrate that only a few 
molecules of each SNARE protein are present on each droplet. 
Thus, the total amount of SNAREs on lipid droplets is low, even 
though most droplets were found to have a positive signal. 
 
It can therefore be concluded that the SNARE proteins SNAP23, 
syntaxin-5, and VAMP4—together with α-SNAP and NSF—are 
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 present on the surface on lipid droplets, where they form a 
functional SNARE complex. 
Lipid droplets fuse using SNARE proteins 
SNAREs are present on lipid droplets and form the expected 
complex. Moreover, it was demonstrated that they are also active 
in the fusion between lipid droplets. This conclusion was based 
on the analysis of the effect of siRNA-mediated ablation of the 
respective protein followed by both lipid droplet size analysis 
and live time-lapse analysis of lipid droplet fusion. Apart from 
siRNA ablations, dominant negative overexpression and 
microinjections were used to reduce protein amounts and to 
assess loss-of-function effects. All reductions in protein levels 
resulted in a reduced frequency of lipid droplet fusion and 
smaller droplets in NIH3T3 cells.  
 
One alternative possibility would be that the fusion between 
droplets is not protein-dependent, and thereby uncoordinated. 
This hypothesis is supported by the fact that pure triglycerides in 
an aqueous solution in vitro readily fuse to form one large fat 
droplet. This is also seen with lipid droplets lacking PAT domain 
protein associations64. Within the cell, however, such an 
organization would be chaotic—with hydrophobic droplets 
fusing in an uncontrolled manner, disrupting cellular architecture 
and clogging all the hydrophobic molecules. A more likely 
situation is the one seen in live cells with lipid droplets coated 
with PAT-domain proteins, which provides an effective way to 
control and organize the droplets. Such a protein coat would 
inhibit spontaneous fusion events between lipid droplets, 
 56
 providing a means of controlling the fusion process using protein 
machinery.  
 
This study is the first report of a functional v-/t-SNARE complex 
containing syntaxin-5, SNAP-23, and VAMP4, which would be 
consistent with the discovery of a previously unknown fusion 
reaction. Because the putative t-SNARE complex, consisting of 
syntaxin-5 and SNAP-23, is new, it is likely to be involved in a 
novel fusion reaction. 
 
Transport vesicles are surrounded by a double phospholipid 
membrane, whereas the lipid droplets are surrounded by a single 
membrane. It is therefore likely that the mechanism of fusion 
between lipid droplets differs from that between transport 
vesicles and target membranes. The most strongly prevailing 
hypothesis of vesicle fusion is the so-called “stalk hypothesis”. 
According to the hypothesis, fusion is the result of an ordered 
sequence of transition states (reviewed in126).  
 
Based on this, a model is therefore proposed in which fusion 
between lipid droplets requires only the first two steps in the 
process proposed for fusion between vesicles and target 
membranes, and is completed at a stage equivalent to the creation 
of the “fusion stalk”, i.e. when the hydrophobic parts of two 
membranes are connected but no aqueous connection has been 
formed (shown in Figure 3). 
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Figure 3. A model of fusion. (a) The first step in the stalk 
hypothesis for the fusion of two bi-layers (adapted from126). The 
outer leaflets fuse and connect the two hydrophobic regions of 
the bi-layer (yellow). The hydrophilic portions of each 
monolayer of the membranes are shown in black. (b) A possible 
model for fusion between two droplets. The formation of the four-
helix bundle between syntaxin-5 (Qa), SNAP23 (Qbc), and 
VAMP4 (R) forces the two monolayers to fuse with each other, 
resulting in a connection between the hydrophobic phases 
(yellow). This is equivalent to the creation of a fusion stalk in (a). 
TG: triglycerides. 
 
SNAP23 as a modulator of fatty acid-induced insulin 
resistance 
The results from paper III reveal that fatty acid treatment reduces 
the insulin-dependent uptake of glucose and the translocation of 
GLUT4 to the plasma membrane by diverting SNAP23 from the 
plasma membrane to the interior of the cell and lipid droplets. 
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 Even though SNAP23 is clearly reduced on the plasma 
membrane upon fatty acid treatment and increased on the lipid 
droplets, the disappearance at the plasma membrane, however, 
represents only 30% of the total pool. Also, the increase in 
SNAP23 on droplets is only a small proportion of the total 
intracellular amount of SNAP23. Thus, the quantitative changes 
in SNAP23 levels would not completely explain the huge effect 
seen on insulin-stimulated glucose uptake and GLUT4 
translocation. There are, however, other mechanisms that might 
additionally explain the dramatic effect of SNAP23. The t-
SNARE complex between SNAP23 and syntaxin-4 that mediates 
the fusion of GLUT4 vesicles to the plasma membrane can be 
disrupted by a protein named Munc18c127. Munc18c binds to 
syntaxin-4 and thereby prevents SNAP23 from binding, thus 
causing insulin resistance127-129. Munc18 is also known to be 
upregulated by fatty acid treatment130. Thus, apart from the 
translocation of SNAP23 seen in paper III, treatment with fatty 
acids might inhibit the t-SNARE complex by increasing the 
protein amount of Munc18c. These two mechanisms together 
could explain the great effect of fatty acids on insulin resistance, 
and also the vital role for SNAP23 in the process. 
 
It has been shown that fatty acid-induced insulin resistance is 
mediated by inactivation of vital signalling kinases downstream 
of the insulin receptor. An example of such a kinase is Protein 
Kinase C δ (PKCδ)131. This could possibly argue against 
SNAP23 as being the only mechanistic mediator of fatty acid-
mediated insulin resistance. On the other hand, it is not unlikely 
that the disruption of the t-SNARE complex for GLUT4-
translocation by fatty acid stimulation would be mediated by 
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 signaling kinases. In fact, SNAP23 has been shown to be 
phosphorylated by PKC132. Also, a protein named Synip has been 
shown to undergo protein-protein interactions with SNAP23, and 
its phosphorlyation is necessary for insulin-dependent glucose 
uptake. Thus, the previously described kinases that are active in 
fatty acid-induced insulin resistance could possibly act by 
disrupting the t-SNARE complex of SNAP23 and syntaxin-4, 
thereby being compatible with the data in paper III. 
 
Taken together, the results presented suggest that translocation of 
SNAP23 is a major mediator of fatty acid-induced insulin 
resistance. 
Proposed model 
The data and discussion from this thesis can be summarized in a 
model in which lipid droplets are formed in association with 
microsomes. The assembly is promoted by insulin and required 
enzymes involved in triglyceride biosynthesis as well as 
phospholipase D1 and ERK2. The two latter proteins are 
necessary for the insulin effect. ERK2 acts by phosphorylating 
dynein, which then translocates to the lipid droplets and 
participates in enlargement of the newly formed droplets. This 
process is illustrated in Figure 4. 
. 
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Figure 4. A model for initial lipid droplet formation, where 
DGAT produces triglycerides between the leaflets of the 
microsomal membrane. A lipid droplet is then formed in 
response to insulin signaling and the activities of PLD1 and 
ERK2. This droplet contains dynein, which mediates the 
enlargement of newly synthesized lipid droplets. 
 
After the initial formation, the droplets increase in size by fusing 
with each other. This fusion is performed on microtubules, and is 
mediated by SNARE proteins—SNAP23, syntaxin-5, and 
VAMP4. Apart from the SNAREs, co-factors such as α-SNAP 
are necessary for the continuation of fusion events. This process 
is illustrated in Figure 5. 
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Figure 5. Model of fusion between small lipid droplets, mediated 
by the SNARE proteins SNAP23, syntaxin-5, and VAMP4. 
 
The final data in this thesis indicate that SNAP23 also 
participates in insulin-mediated translocation of GLUT4 to the 
plasma membrane, thus causing glucose uptake. When lipid 
biosynthesis is activated, SNAP23 is redistributed from the 
plasma membrane to lipid droplets—causing a defect in the 
insulin signalling and thereby insulin resistance. 
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